Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 4/20 | 0.42 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 7/20 | 0.34 |
| ▸ | GBA1 | P04062 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LCT | P09848 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20225057 | 1.00 | MGAM (0.42) | MGAMFUCA1GAAGBA1TDP1 | |
| SCHEMBL12909426 | 1.00 | MGAM (0.42) | MGAMFUCA1GAAGBA1TDP1 | |
| SCHEMBL12945229 | 0.84 | MGAM (0.39) | MGAMFUCA1GAAGBA1 | |
| SCHEMBL17795736 | 0.81 | MGAM (0.38) | MGAMFUCA1GAAGBA1 | |
| SCHEMBL17795737 | 0.81 | MGAM (0.38) | MGAMFUCA1GAAGBA1 | |
| SCHEMBL12909428 | 0.78 | GABRP (0.36) | MGAMFUCA1TDP1 | |
| SCHEMBL17792246 | 0.77 | MGAM (0.48) | MGAMFUCA1GAAGBA1TDP1 | |
| SCHEMBL22693291 | 0.77 | MGAM (0.48) | MGAMFUCA1GAAGBA1TDP1 | |
| SCHEMBL2437299 | 0.71 | GAA (0.59) | MGAMGAAGBA1TDP1LCT | |
| SCHEMBL12909423 | 0.71 | GAA (0.59) | MGAMGAAGBA1TDP1LCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | VIDA PHARMA LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| US-10842784-B2 | Treatment of energy utilization disease | VIDA PHARMA LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| EP-2257286-B1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORP PLC (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | SUMMIT CORPORATION PLC (GB) | 2011-01-20 | — | — | US | disclosed |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | SUMMIT CORPORATION PLC (GB) | 2011-01-20 | — | — | US | disclosed |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | SUMMIT CORPORATION PLC (GB) | 2011-01-20 | — | — | US | disclosed |
| WO-2009103953-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | SUMMIT CORPORATION PLC (GB) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | IRS1, SLC2A1, INSR | MGAM 97/4885FUCA1 1506/4885GAA 268/4885 |
| US-20110015226-A1 | Treatment of Energy Utilization Disease | IRS1, SLC2A1, INSR | MGAM 97/4885FUCA1 1506/4885GAA 268/4885 |
| US-20160151341-A1 | TREATMENT OF ENERGY UTILIZATION DISEASE | IRS1, SLC2A1, INSR | MGAM 97/4885FUCA1 1506/4885GAA 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.